New Federal Contractors — August 09, 2026

The $626.5 million firm-fixed-price contract for smallpox antiviral development and procurement, with $447.2 million already outlayed, provides multi-year revenue visibility through 2029 and signals strong government commitment to biodefense preparedness.

The $209.2 million firm-fixed-price delivery order for medical disability examinations in the Southeast region was fully executed by September 2021, with $196.6 million outlayed, representing a completed revenue stream for Leidos with potential for follow-on contracts.

The non-competed, time-and-materials contract for legal services has a short 6-month base period and potential total value of $244 million if options are exercised, but the contract type exposes the government to cost overruns and limits competitive visibility.

SIGA Technologies faces medium execution risk on its $626.5M fixed-price contract; cost overruns could compress margins despite the long-term revenue stream.

OUR RESCUE's $158.1M HHS contract has a short 6-month base period ending February 2027; option exercise depends on HHS budget continuity and could be disrupted by a government shutdown or CR.

SIGA's contract was awarded under full-and-open competition, leaving it vulnerable to future competitive re-solicitations for follow-on biodefense contracts.

Two of three contracts (SIGA and OUR RESCUE) are from HHS, representing $784.6 million or 79% of total obligation, creating agency-specific concentration risk for investors tracking health sector exposure.

SIGA Technologies' $626.5M contract provides a long-term revenue base through 2029, with potential for additional BARDA contracts in antiviral development as biodefense priorities expand.

Leidos' QTC Medical Services completed a $209.2M VA contract; follow-on VA medical examination contracts in other regions could provide recurring revenue for Leidos.

OUR RESCUE's $158.1M sole-source HHS contract could lead to option exercises worth up to $244 million total, providing near-term revenue if the bridge contract is extended.

SIGA Technologies' $626.5M HHS/BARDA contract for smallpox antiviral development underscores sustained government commitment to biodefense, with long-term funding visibility through 2029.

Leidos' QTC Medical Services completed a $209.2M VA contract for medical disability examinations, indicating stable demand for outsourced medical evaluation services from the VA.

OUR RESCUE's $158.1M sole-source HHS legal services contract reflects agency reliance on non-competed bridge awards to maintain continuity, but the time-and-materials structure introduces cost risk.

{"entity" => "SIGA Technologies", "reason" => "Long-term $626.5M biodefense contract with medium execution risk; cost performance and option exercises are key.", "trigger" => "Quarterly earnings reports; BARDA option exercise announcements; new antiviral solicitations"}

{"entity" => "Leidos Holdings", "reason" => "Completed $209.2M VA contract; potential for follow-on medical exam contracts in other regions.", "trigger" => "VA re-compete announcements for medical disability examinations"}

{"entity" => "OUR RESCUE", "reason" => "$158.1M HHS bridge contract with high pricing risk; option exercise by February 2027 is critical.", "trigger" => "HHS option exercise decision; protests or competitive re-solicitations for follow-on legal services"}

{"entity" => "HHS", "reason" => "Dominant agency in this digest, accounting for 79% of total obligation; budget continuity affects both SIGA and OUR RESCUE.", "trigger" => "CR resolution; HHS budget proposals; BARDA funding levels in NDAA"}